We’re developing safe, effective drugs to combat bioterrorism and infectious disease.

Emerging biological and chemical threats pose a significant risk to national security and public health.

Governments everywhere are increasingly vigilant and investing billions of dollars in preparation for potential bioterrorism attacks and pandemic diseases.

AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally occurring infectious diseases.

Our growing portfolio responds to the demand for safe, effective therapeutics for national stockpiles against a range of threats from weaponized toxic agents such as the ricin and sarin to viruses such as Ebola.

Read more.

Our versatile, scalable platform is ideal for novel indications and new markets. AntoXa holds an exclusive licence to use PlantForm Corporation’s vivoXPRESS^® biopharmaceutical manufacturing platform to produce countermeasures for ricin, sarin, soman and Ebola Sudan, as well as other biodefense therapeutics.

Key advantages of the vivoXPRESS® platform include:

• rapid drug development and production timelines
• high levels of drug expression
• mammalian-type glycosylation (less risk of unwanted immune reactions)
• reduced risk profiles versatility (for new product development)
• unlimited scale-up capability (to respond quickly to increased demand), and
• manufacturing costs as much as 90 per cent lower than those for mammalian cell technology systems.

Read more.